Who is sponsoring NCT05172869?

NCT05172869 is sponsored by Ankara City Hospital Bilkent.

What drugs are being tested in NCT05172869?

Interventions in NCT05172869: Suprainguinal Performed FICB, Infrainguinal Performed FICB.

What condition does NCT05172869 study?

NCT05172869 studies Femoral Fractures, Postoperative Pain.

Is NCT05172869 still recruiting?

NCT05172869 is currently completed. Last updated 1 December 2022.

Last reviewed 2022-12-01 · How we verify

NCT05172869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Two Different Approaches in the Fascia Iliaca Compartment Block in Femoral Fracture Surgery

Completed NA Last updated 1 December 2022

What this trial tests

NA trial testing Suprainguinal Performed FICB in Femoral Fractures in 68 participants. Completed in 27 November 2022.

Timeline

9 February 2022

Primary endpoint
30 April 2022

27 November 2022

Quick facts

Lead sponsor	Ankara City Hospital Bilkent
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	68
Start date	9 February 2022
Primary completion	30 April 2022
Estimated completion	27 November 2022
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Suprainguinal Performed FICB
Infrainguinal Performed FICB

Conditions studied

Femoral Fractures — all drugs for Femoral Fractures →
Postoperative Pain — all drugs for Postoperative Pain →

Sponsor

Ankara City Hospital Bilkent

Who can join

18 and older, any sex, with Femoral Fractures or Postoperative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Fascia Iliaca Compartment Block (FICB) is a popular regional anaesthetic technique for surgical procedures involving the hip joint and femur. The FICB may be thought of as an anterior approach to the lumbar plexus where local anaesthetic is injected proximally beneath the fascia iliaca, with the aim of blocking the femoral nerve ,obturator nerve and lateral cutaneous nerve of thigh simultaneously. In addition to providing effective analgesia, peripheral nerve blocks are increasingly preferred especially in frail patient groups such as the geriatric population which femoral fractures are the most common, because of their advantages such as avoiding the complications of neuraxial anesthesia and the side effects of opioids. FICB can be applied with ultrasound-guided suprainguinal or infrainguinal approaches. Studies on the superiority of the two methods used in clinical practice are limited. In this study, it is aimed to compare the suprainguinal (Group S) and infrainguinal (Group I) approaches of FICB applied in the preoperative period in femoral fractures in which spinal anesthesia method was chosen. These two methods will be compared in terms of postoperative pain scores (11-point numeric scale), morphine consumption (by intravenous patient controlled analgesia for postoperative 24 hours) and possible side effects-complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ankara City Hospital Bilkent trials

Trials by the same sponsor.

NCT07496788 — Investigation of the Role of Internal Jugular Vein Collapsibility Index in Predicting Spinal Anesthesia-Induced Hypotens · not yet recruiting
NCT07536464 — PEEP Strategies and Mechanical Power in Robotic Surgery · NA · not yet recruiting
NCT07534553 — Mechanical Power Ventilation in RALP · NA · not yet recruiting
NCT07501468 — Ventilation Safety in Beach Chair Shoulder Surgery: SafeLM Versus I-gel · NA · not yet recruiting
NCT07502209 — Suprascapular Nerve PRF in Chronic Shoulder Pain · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05172869 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ankara City Hospital Bilkent
Last refreshed: 1 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05172869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing